SCG Cell Therapy

We are thrilled to announce late-breaking data from our Phase 1 trial of SCG101, our first-in-class HBV-specific TCR-T therapy, presented at the 2024 AASLD Liver Meeting in San Diego! The results are incredibly promising: - All patients showed a significant reduction in serum HBsAg levels, with 92% of patients achieving a reduction of 1.0 to 4.6 log - 33% experienced HBsAg loss within 21 days - SCG101 also demonstrated favorable safety and tolerability These findings represent a significant milestone in the development of innovative immunotherapies for HBV infection and HBV-related cancers, further underscoring the potential of our GianTCR discovery platform to revolutionize treatment options for infection-associated cancers. We're excited to continue advancing SCG101 and bring hope to patients battling this devastating disease. For the full press release, please visit: https://lnkd.in/gdbywNut #biotech #immunotherapy #SCG101 #TCRT #HBV #hepatocellularcarcinoma #livercancer #AASLD2024 #innovation #clinicaltrials

Dr. Karin Wisskirchen, Head of Research of SCG, had the honor of giving a presentation at the HBV Cure Workshop 2024 in San Diego. It was a fantastic opportunity to discuss the latest advancements and strategies in curing Hepatitis B with scientific and industry experts. Many thanks to all participants for the inspiring exchange and insightful discussions! We look forward to continuing to drive innovative solutions for HBV therapy. #SCGCellTherapy #HBVCure #HepatitisB #CellTherapy

Exciting news from SCG Cell Therapy! FDA approved IND application for Phase 1/2 clinical trial of SCG142, a novel next generation TCR T cell therapy for HPV-associated solid tumors. This is another FDA approved TCR-T cell therapy candidate generated from our proprietary GianTCRᵀᴹ platform, representing the advancement of our TCR-based therapeutic program to treat unmet needs in different major cancer indications.   For the full press release, please visit: https://lnkd.in/gCs7BkGR #Immunotherapy #CellTherapy #TCRT #CancerResearch #FDAApproval #HPV

Exciting news from SCG Cell Therapy! Our groundbreaking TCR-T cell therapy — SCG101 therapy was featured in a late-breaking session at the EASL Congress 2024 in Milan. Selected for the Best of EASL Congress Wrap-Up summary, highlighting significantly improved overall survival and sustained HBsAg clearance in patients with HBV-related Hepatocellular Carcinoma. Proud to be at the forefront of innovation in fighting infectious diseases and associated cancers. For the full press release, please visit: https://lnkd.in/gpyBGdck #SCGCellTherapy #EASLCongress2024 #Immunotherapy #HBV

SCG Cell Therapy is delighted to announce upcoming Late-breaking poster presentation at the EASL Congress 2024 in Milan, Italy. We are excited to share our clinical breakthrough with SCG101: HBV-specific TCR-T cell therapy in HBV-related hepatocellular carcinoma (HCC).  Abstract Number: LB113 Title: First-in-human Clinical Result of a Novel HBV-specific TCR T Cell Therapy (SCG101) in Patients With HBV-related Hepatocellular Carcinoma (HCC) Date: June 5-8, 2024 Location: Allianz MiCo, Milan, Italy

Exciting update from Dr. Susanne Wilde, Head of Preclinical Research at SCG Cell Therapy, sharing groundbreaking findings at ASGCT 2024 Annual Meeting in an oral presentation! The latest preclinical data showcasing SCG142 superior tumor inhibition with our Immunoswitch Armoured HPV-TCR T Cell Therapy against a spectrum of HPV-associated cancers. For the full press release, please visit: https://lnkd.in/gmzc2dyu #ASGCT2024 #CancerResearch #Immunotherapy #TCR #SCG Cell Therapy

SCG Cell Therapy is delighted to announce upcoming oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland. The presentation will describe promising preclinical data of HPV-specific TCR T therapy (SCG142), highlighting positive results of the next generation TCR T cell to enhance T cell functionality and overcame the inhibitory tumor microenvironment. Abstract Number: 416 Title: A high-avidity, CD8-co-receptor-independent, HPV-specific TCR coupled with a TGF-β chimeric switch receptor enhances polyfunctional profiles and anti-tumor activities in HPV-16/52-associated cancers Session Day and Time: Saturday, May 11, 2024 10:30 a.m. - 10:45 a.m. EST Location: Room 318-323, Baltimore International Convention Center

Thrilled to share insights of “Development of TCR-Based Cellular Immunotherapy for Solid Tumor" and participated in the panel discussion on “Asia’s Role is Shaping the Future of Cell Therapy” by Christy Ma, Chief Strategy Officer at SCG Cell Therapy, at the 2nd Cell and Gene R&D Congress in Singapore. Let’s together explore innovation, collaboration, and market trends in advancing cellular immunotherapy. #CellTherapy #Innovation #Collaboration #CGT #Immunotherapy #SCGCellTherapy

We are thrilled to announce the launch of the Joint Laboratories For Cellular Immunotherapies by SCG Cell Therapy and A*STAR! With a combined funding of close to S$30 million supported by Singapore’s Research, Innovation and Enterprise 2025 Plan (RIE2025). This first-of-its-kind joint collaboration, established at SCG’s GMP facility and A*STAR’s research facility, leverage SCG’s and A*STAR’s proprietary technologies to develop scalable GMP-grade iPSC and therapeutic products. The joint lab also serve as a platform for nurturing the next generation of talent in this transformative field. Stay tuned for more updates as we embark on this groundbreaking endeavor together. For the full press release, please visit: https://lnkd.in/gWNsy6un #CellTherapy #Immunotherapy #Innovation #SCGCellTherapy #Astar #Collaboration #RegenerativeMedicine #BTI #IMCB